In January 2018, it was announced that five healthcare systems were launching a not-for-profit generic drug company. That company now has a name, Civica Rx.
FCB Health Network, the 2018 Cannes Lions “Healthcare Network of the Year,” announced the launch of FCB Health Brasil.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
The CME provider Rockpointe launched the first CME-certified course ever offered on Amazon Echo through the AudioEducate platform with joint providers Potomac Center for Medical Education (PCME) and the Academy of Physicians in Clinical Research (APCR).
Agency veterans Mike Myers and Steve Bernstein launched a new strategic and creative agency model called CrowdPharm.
Novartis’ foray into digital technology intensified as the Swiss drugmaker launched a mobile-phone based app to help collect data from people participating in eye disease studies.
Foghorn Therapeutics, based in Cambridge, Massachusetts, officially launched with a $50 million investment from Flagship Pioneering and associated investors.
With a high-profile group of investors and backers, Celgene Corp. spinout Celularity launched with $250 million.
One week after launching, Partner Therapeutics acquired the global rights to Leukine (sargramaostin) from Paris-based Sanofi.